Loading
Chronotherapy / Phototherapy / Major Depressive Disorder · Journal article
Annals of Medicine · June 3, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes evidence linking circadian rhythm disruption to MDD pathophysiology through genetic variants (CLOCK, TIMELESS, CRY1), dysregulated hypothalamus-pituitary-adrenal axis function, and abnormal melatonin signaling. The authors propose that circadian dysfunction may be causal in MDD and advocate for personalized circadian-based therapeutic approaches including light therapy and sleep interventions, though the review does not report quantified treatment efficacy or a systematic appraisal of evidence quality.
Narrative review. Literature on circadian rhythm disruption and major depressive disorder; experimental, translational, and clinical studies.
Genetic studies identified variants in core clock genes (CLOCK, TIMELESS, CRY1) correlating with both circadian disruption and MDD susceptibility Preclinical models demonstrate dysregulation of core clock genes (Bmal1, Per1, Per2) in treatment-resistant depression Wearable-based longitudinal studies reveal bidirectional relationships between sleep-wake cycles, circadian rhythms, and mood
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review offers clinicians a conceptual framework for understanding MDD through the lens of circadian biology and suggests emerging therapeutic targets (light therapy, sleep interventions, pharmacology targeting clock genes). However, the review does not quantify treatment effect sizes or provide direct evidence on which interventions have been validated in trials, limiting its immediate prescriptive utility.
This is a narrative review synthesizing mechanistic and clinical evidence on circadian rhythm disruption in MDD, offering conceptual synthesis and therapeutic direction without conducting systematic appraisal or reporting original trial data.
As stated by the source record.
Quoted from the source exactly as published.
This review offers clinicians a conceptual framework for understanding MDD through the lens of circadian biology and suggests emerging therapeutic targets (light therapy, sleep interventions, pharmacology targeting clock genes). However, the review does not quantify treatment effect sizes or provide direct evidence on which interventions have been validated in trials, limiting its immediate prescriptive utility.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Major Depressive Disorder (MDD) has emerged as a leading cause of disability worldwide, affecting over 264 million people. Recent evidence reveals that disruption of circadian rhythms may be fundamental to MDD pathophysiology, opening new avenues for therapeutic intervention.Methods. This review synthesizes current understanding of the intricate relationship between circadian system disruption and MDD, highlighting molecular mechanisms and clinical implications. We examine evidence from genetic studies, clinical observations, and therapeutic trials.Results. Patients with MDD exhibit profound alterations in circadian-regulated processes, including sleep-wake cycles, diurnal mood patterns, and metabolic functions. Genetic studies have identified variants in core clock genes, particularly CLOCK, TIMELESS, and CRY1, that correlate with both circadian disruption and MDD susceptibility. These genetic insights, combined with evidence of dysregulated hypothalamus-pituitary-adrenal axis function and abnormal melatonin signaling, suggest that circadian dysfunction may be causal in MDD pathogenesis rather than merely symptomatic.Conclusions. Emerging chronotherapeutic approaches, such as light therapy, sleep interventions, and targeted pharmacology, show significant potential for improving depressive symptoms. Personalized circadian-based treatments, guided by genetic and molecular markers, could transform MDD care. Advancing our understanding of the circadian-depression connection offers a promising path to revolutionizing treatment strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.